ANI Pharmaceuticals (NASDAQ:ANIP) Upgraded at Leerink Partnrs

Leerink Partnrs upgraded shares of ANI Pharmaceuticals (NASDAQ:ANIP) to a strong-buy rating in a report released on Wednesday,Zacks.com reports.

Other equities analysts also recently issued reports about the company. HC Wainwright restated a “buy” rating and issued a $94.00 price target on shares of ANI Pharmaceuticals in a research note on Monday, November 11th. Piper Sandler initiated coverage on ANI Pharmaceuticals in a research report on Friday, October 11th. They issued an “overweight” rating and a $68.00 target price on the stock. Leerink Partners started coverage on shares of ANI Pharmaceuticals in a research report on Wednesday. They set an “outperform” rating and a $80.00 price target for the company. Truist Financial raised their price objective on shares of ANI Pharmaceuticals from $60.00 to $62.00 and gave the stock a “hold” rating in a report on Tuesday, October 22nd. Finally, StockNews.com cut shares of ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, September 7th. Two investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, ANI Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $77.71.

ANI Pharmaceuticals Price Performance

Shares of NASDAQ:ANIP opened at $56.59 on Wednesday. The company has a debt-to-equity ratio of 1.52, a quick ratio of 1.97 and a current ratio of 2.74. The firm has a market cap of $1.19 billion, a price-to-earnings ratio of -102.89 and a beta of 0.73. The business has a 50-day simple moving average of $58.01 and a two-hundred day simple moving average of $60.33. ANI Pharmaceuticals has a fifty-two week low of $51.79 and a fifty-two week high of $70.81.

ANI Pharmaceuticals (NASDAQ:ANIP) last released its quarterly earnings data on Friday, November 8th. The specialty pharmaceutical company reported $1.34 earnings per share for the quarter, beating the consensus estimate of $1.09 by $0.25. The firm had revenue of $148.30 million during the quarter, compared to analysts’ expectations of $144.37 million. ANI Pharmaceuticals had a negative net margin of 1.28% and a positive return on equity of 15.87%. The firm’s quarterly revenue was up 12.5% on a year-over-year basis. During the same period in the previous year, the company earned $1.05 earnings per share. On average, analysts expect that ANI Pharmaceuticals will post 3.87 earnings per share for the current year.

Insiders Place Their Bets

In other news, SVP Krista Davis sold 1,000 shares of the business’s stock in a transaction dated Wednesday, December 11th. The stock was sold at an average price of $60.00, for a total value of $60,000.00. Following the transaction, the senior vice president now directly owns 49,059 shares in the company, valued at $2,943,540. The trade was a 2.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Nikhil Lalwani sold 33,481 shares of the stock in a transaction dated Tuesday, November 26th. The stock was sold at an average price of $57.99, for a total value of $1,941,563.19. Following the sale, the chief executive officer now owns 370,378 shares of the company’s stock, valued at $21,478,220.22. This represents a 8.29 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 34,731 shares of company stock worth $2,015,861 over the last three months. 12.70% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On ANI Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the stock. Global Alpha Capital Management Ltd. increased its holdings in ANI Pharmaceuticals by 1.8% in the 3rd quarter. Global Alpha Capital Management Ltd. now owns 536,450 shares of the specialty pharmaceutical company’s stock valued at $32,005,000 after acquiring an additional 9,500 shares during the last quarter. Sequoia Financial Advisors LLC bought a new stake in shares of ANI Pharmaceuticals in the second quarter worth about $600,000. Susquehanna Fundamental Investments LLC purchased a new stake in shares of ANI Pharmaceuticals in the second quarter worth about $228,000. Thompson Siegel & Walmsley LLC boosted its stake in ANI Pharmaceuticals by 17.6% during the third quarter. Thompson Siegel & Walmsley LLC now owns 230,159 shares of the specialty pharmaceutical company’s stock valued at $13,731,000 after buying an additional 34,416 shares during the last quarter. Finally, Thrivent Financial for Lutherans boosted its stake in ANI Pharmaceuticals by 2.3% during the third quarter. Thrivent Financial for Lutherans now owns 13,028 shares of the specialty pharmaceutical company’s stock valued at $777,000 after buying an additional 299 shares during the last quarter. Institutional investors own 76.05% of the company’s stock.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.